#bes16

[bioeuropespring-blog]

Immuno therapies are the current treatment focus and likely future favorites, meaning asset asking prices are inflated

Jan Lundberg, president of Lilly Research Labs

[bioeuropespring-blog]

The reimbursement challenge will be most acute in immuno-oncology combinations

Bernd Seizinger, Aprea AB chair told the audience of BIO-Europe Spring's Environment In 2016

[bioeuropespring-blog]

Sanofi will soon be launching a series of incubators to advance early- stage, innovative drug development program on both the East and West coasts in the US

Sarah Holland, head of Europe, external science and partnering, told her panel audience at BIO-Europe Spring

[bioeuropespring-blog]

Which Company Has The Most Partnering Opportunities In Its Pipeline?

Get a copy of Medtrack's new report, Unpartnered Products: 2015 Update, at BIO-Europe Spring to find out which private and public life science companies have the highest number of programs ripe for partnering opportunities.

Medtrack has selected the top opportunities for partnering by narrowing down its search to private companies and public companies with less than one year of cash available (according to latest balance sheets/annual cash burn rate) with unpartnered pipeline assets.

Omeros Corporation has taken the top spot in the public sector with a total of 38 unpartnered programs in its pipeline, split as 36 preclinical assets and two Phase II opportunities. Omeros, which was previously ranked in fourth position a year earlier, is closely followed by Sarepta Therapeutics in second place. Sarepta has a total of 25 unpartnered programs, one research program, 18 preclinical assets, four Phase I candidates and two Phase II drugs. Other companies finishing off the top five in the public sector are: Skinvisible Inc (21 products), Anavex Life Sciences Corp (16), and GlobeImmune (15).

In the private sector, the company with the most unpartnered programs is Aphios Corporation, which was also ranked at number one in the previous analysis by MedTrack. Aphios has 32 unpartnered products five in research stages, 25 preclinical assets, one Phase II and one Phase III opportunity. Making up the rest of the top five for private firms is Deciphera Pharmaceuticals LLC with 27 programs, Microbiotix Inc (26), Celprogen Inc (22), and Chikujee Therapeutics (21).

In big pharma, MedTrack has looked specifically at companies with unpartnered Phase III candidates in all therapeutic areas. This field includes, Novartis' breast cancer drug BKM120 and acute myeloid leukemia therapy PKC412; Bristol-Myer's Squibb's HIV drug BMS663068; Amgen's migraine product AMG334; and Novo Nordisk's non-insulin-dependent diabetes therapy NN9535.

MedTrack analysts noted in the report that the number of big pharma out-licensing deals has almost doubled between 2010 and 2014. They highlighted Amgen's migraine drug as a potential opportunity for a neurology firm, as Amgen doesn't have neurology as a key focus area and may seek a licensee with experience in a field. However, the drug is partnered regionally with Novartis as of September 2015.

Overall, Sanofi has the most unlicensed candidates in Phase III, with 10 in total, many of which fall into the infectious disease field. Most unpartnered big pharma Phase III products belong to the infectious disease space.

MedTrack's full report is available at BIO-Europe Spring and online.